JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 114 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $59,679 | +66.7% | 32,259 | 0.0% | 0.02% | +53.3% |
| Q4 2022 | $35,807 | -52.3% | 32,259 | 0.0% | 0.02% | -53.1% |
| Q3 2022 | $75,000 | -23.5% | 32,259 | 0.0% | 0.03% | -23.8% |
| Q2 2022 | $98,000 | -55.3% | 32,259 | 0.0% | 0.04% | -45.5% |
| Q1 2022 | $219,000 | -1.4% | 32,259 | +21.4% | 0.08% | +5.5% |
| Q4 2021 | $222,000 | +12.1% | 26,582 | -0.4% | 0.07% | +7.4% |
| Q3 2021 | $198,000 | +51.1% | 26,684 | +38.8% | 0.07% | +58.1% |
| Q2 2021 | $131,000 | -0.8% | 19,221 | +49.6% | 0.04% | -12.2% |
| Q1 2021 | $132,000 | – | 12,844 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |